2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Burkholderia Infections: new trials by email Literature Review of Burkholderia Infections trials Research Report on Burkholderia Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients Ceftazidime or meropenem, ARV-1801, Placebo - Melioidosis | Phase 2 | Completed | Arrevus Inc. | 125 | 2022-06-14 | 2024-02-16 |
| A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection Alginate oligosaccharide, Placebo - Cystic Fibrosis, Burkholderia Infection | Phase 2 | Completed | AlgiPharma AS | 15 | 2015-02-01 | 2018-04-19 |
Cystic Fibrosis (1) · Melioidosis (1)
Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Negative Bacterial Infections (2) · Infections (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Genetic Diseases, Inborn (1) · Infant, Newborn, Diseases (1) · Lung Diseases (1) · Pancreatic Diseases (1) · Respiratory Tract Diseases (1)
Ceftazidime (1) · Meropenem (1) · oligoG CF-5-20 (1)
AlgiPharma AS (1) · Arrevus Inc. (1)
Germany (1) · Thailand (1)